{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:20:18Z","timestamp":1794583218551,"version":"4.9.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Abnormal lipid distribution is observed in patients with psoriasis, which increases their risk for atherosclerosis. Lipid-lowering drugs have a certain curative effect in the treatment of psoriasis, but there is no relevant evidence-based medical evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this systematic evaluation was to assess the efficacy, safety, and potential mechanisms of action of lipid-lowering drugs for the treatment of psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trial, Chinese National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database, and Wanfang Database were searched for relevant articles from inception to 31 December 2021. The RevMan 5.3 and Cochrane risk-of-bias tool were used for data analysis and risk assessment, respectively. The psoriasis area and severity index (PASI) score is the primary outcome indicator in clinical studies. Based on preclinical studies, we elucidated and mapped the action mechanisms of lipid-lowering drugs in the treatment of psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included eight randomized controlled studies, four single-arm studies, and four <jats:italic>in vitro<\/jats:italic> studies. The results showed that lipid-lowering drugs, particularly statins, administered both orally and topically, can significantly improve psoriatic skin lesions and reduce the PASI scores [standardized mean difference, (SMD): \u22120.94; 95% CI: [\u22121.58, \u22120.31]; <jats:italic>p<\/jats:italic> = 0.004]. Oral statins performed best at week eight (SMD: \u22120.92; 95% CI: [\u22121.39, \u22120.44]; <jats:italic>p<\/jats:italic> = 0.0001). The mechanism of lipid-lowering drugs in the treatment of psoriasis may be related to the inhibition of keratinocyte proliferation, inhibition of CCL20\u2013CCR6 interaction, and reduction in the levels of inflammatory factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>There are few studies on lipid-lowering drugs and psoriasis, and their small sample sizes may render the evidence unconvincing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present findings suggest that lipid-lowering drugs are relieving symptoms in psoriasis. Lipid-lowering drugs, particularly statins, can be used to treat psoriasis with good efficacy and few side effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.900916","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:11:19Z","timestamp":1660212679000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Current evidence on the role of lipid lowering drugs in the treatment of psoriasis"],"prefix":"10.3389","volume":"9","author":[{"given":"Jiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokgyeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.759276","article-title":"Sphingosine-1-phosphate and its signal modulators alleviate psoriasis-like dermatitis: preclinical and clinical evidence and possible mechanisms.","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.7818","article-title":"Evidence and potential mechanism of action of Lithospermum erythrorhizon and its active components for psoriasis.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18296","article-title":"Global prevalence of metabolic syndrome in patients with psoriasis in the past two decades: current evidence.","author":"Liu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.dsx.2019.01.009","article-title":"The association between psoriasis and diabetes mellitus: a systematic review and meta-analysis.","volume":"13","author":"Mamizadeh","year":"2019","journal-title":"Diabetes Metab Syndr."},{"key":"B6","article-title":"Epidemiology and clinical features of adult patients with psoriasis in malaysia: 10-year review from the malaysian psoriasis registry (2007-2016).","volume":"2018","author":"Affandi","year":"2018","journal-title":"Dermatol Res Pract."},{"key":"B7","article-title":"Association between the apolipoprotein E (ApoE) gene polymorphism, the serum apoe and the metabolic syndrome with psoriasis.","volume":"27","author":"Abdel Hay","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.5543\/tkda.2012.54920","article-title":"Determination of subclinical atherosclerosis in plaque type psoriasis patients without traditional risk factors for atherosclerosis.","volume":"40","author":"Altekin","year":"2012","journal-title":"Turk Kardiyoloji Dernegi Arsivi."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1016\/j.biocel.2008.10.022","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis.","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse events associated with anti-IL-23 agents: clinical evidence and possible mechanisms.","volume":"12","author":"Ru","year":"2021","journal-title":"Front Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cbf.2857","article-title":"Serum lipid profile in psoriatic patients: correlation between vascular adhesion protein 1 and lipoprotein (a).","volume":"31","author":"Nemati","year":"2013","journal-title":"Cell Biochem Funct."},{"key":"B15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/s0009-8981(02)00373-x","article-title":"Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant\u2013antioxidant system in patients with psoriasis.","volume":"328","author":"Kural","year":"2003","journal-title":"Clin Chim Acta."},{"key":"B16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/jid.2009.321","article-title":"Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort.","volume":"130","author":"Wakkee","year":"2010","journal-title":"J Invest Dermatol."},{"key":"B17","article-title":"The effect of inflammation and infection on lipids and lipoproteins.","author":"Feingold","year":"2022","journal-title":"BTI Endotext."},{"key":"B18","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-4632.2010.04579.x","article-title":"Statins in dermatology.","volume":"49","author":"Jowkar","year":"2010","journal-title":"Int J Dermatol."},{"key":"B19","article-title":"Statins, other antihyperlipidemic agents, and psoriasis.","volume":"18","author":"Brauchli","year":"2009","journal-title":"Pharmacoepidemiol Drug Safety."},{"key":"B20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00abs-8.x","article-title":"Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.","volume":"115","author":"Krueger","year":"2000","journal-title":"J Invest Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/MAJ.0b013e3181e2b353","article-title":"Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction.","volume":"340","author":"Xu","year":"2010","journal-title":"Am J Med Sci."},{"key":"B23","first-page":"37","article-title":"Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension.","volume":"50","author":"Vasiuk","year":"2010","journal-title":"Kardiologiia."},{"key":"B24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1592\/phco.27.3.412","article-title":"Fibrates: what have we learned in the past 40 years?","volume":"27","author":"Backes","year":"2007","journal-title":"Pharmacotherapy."},{"key":"B25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/092986709787458416","article-title":"Anti-inflammatory effects of fibrates: an overview.","volume":"16","author":"Tziomalos","year":"2009","journal-title":"Curr Med Chem."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100306","article-title":"Dimethyl fumarate and its esters: a drug with broad clinical utility?","volume":"13","author":"Kourakis","year":"2020","journal-title":"Pharmaceuticals."},{"key":"B27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-015-6588-3","article-title":"PCSK9 inhibition: discovery, current evidence, and potential effects on LDL-C and Lp(a).","volume":"29","author":"Ferdinand","year":"2015","journal-title":"Cardiovasc Drugs Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4314\/njm.v19i1.54216","article-title":"The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study.","volume":"19","author":"Naseri","year":"2010","journal-title":"Niger J Med."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.124639","article-title":"Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis.","volume":"3","author":"Iraji","year":"2014","journal-title":"Adv Biomed Res."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1592\/phco.31.11.1045","article-title":"Atorvastatin for the treatment of plaque-type psoriasis.","volume":"31","author":"Faghihi","year":"2011","journal-title":"Pharmacotherapy."},{"key":"B31","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/00365513.2011.559552","article-title":"Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis\u2013a pilot study.","volume":"71","author":"Morken","year":"2011","journal-title":"Scand J Clin Lab Investig."},{"key":"B32","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40261-017-0533-0","article-title":"Effectiveness of lipid-lowering statin therapy in patients with and without psoriasis.","volume":"37","author":"Ports","year":"2017","journal-title":"Clin Drug Investig."},{"key":"B33","doi-asserted-by":"crossref","first-page":"776","DOI":"10.5958\/0976-5506.2018.01938.1","article-title":"Effect of oral simvastatin therapy on patients with plaque psoriasis treated with potent topical steroid.","volume":"9","author":"Al-Shimary","year":"2018","journal-title":"Indian J Public Health Res Dev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3889\/oamjms.2019.060","article-title":"Efficacy of adding oral simvastatin to topical therapy for treatment of psoriasis: the Vietnamese experience.","volume":"7","author":"Trong","year":"2019","journal-title":"Open Access Maced J Med Sci."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15075","article-title":"Oral simvastatin combined with narrowband UVB for the treatment of psoriasis: a randomized controlled trial.","volume":"34","author":"Al Salman","year":"2021","journal-title":"Dermatol Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jaad.2007.05.040","article-title":"Efficacy of simvastatin in plaque psoriasis: a pilot study.","volume":"57","author":"Shirinsky","year":"2007","journal-title":"J Am Acad Dermatol."},{"key":"B37","first-page":"310","article-title":"Efficacy and safety of simvastatin in chronic plaque psoriasis.","volume":"23","author":"Aslam","year":"2013","journal-title":"J Pak Assoc Dermatol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bjd.13850","article-title":"Adherence to statins and the risk of psoriasis: a population-based cohort study.","volume":"173","author":"Chodick","year":"2015","journal-title":"Br J Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.12669\/pjms.336.14068","article-title":"Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis.","volume":"33","author":"Asad","year":"2017","journal-title":"Pak J Med Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0923-1811(98)00023-1","article-title":"Taurin-conjugated ursodeoxycholic acid has a reversible inhibitory effect on human keratinocyte growth.","volume":"18","author":"Yamaguchi","year":"1998","journal-title":"J Dermatol Sci."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01343.x","article-title":"Statins inhibit chemotactic interaction between CCL20 and CCR6 in vitro: possible relevance to psoriasis treatment.","volume":"131","author":"Kim","year":"2011","journal-title":"J Investig Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s12272-014-0496-0","article-title":"Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-\u03baB activation.","volume":"38","author":"Kulkarni","year":"2015","journal-title":"Arch Pharm Res."},{"key":"B43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12257-020-0368-z","article-title":"Regulatory effect on skin differentiation by mevastatin in psoriasis model using TNF-\u03b1 and IL-17 Induced HaCaT Cells.","volume":"26","author":"Kim","year":"2021","journal-title":"Biotechnol Bioprocess Eng."},{"key":"B44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/nutrit\/nuz098","article-title":"Efficacy of fish oil and its components in the management of psoriasis: a systematic review of 18 randomized controlled trials.","volume":"78","author":"Chen","year":"2020","journal-title":"Nutr Rev."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3507","article-title":"A randomized, double-blind, placebo-controlled clinical study to investigate the efficacy of herring roe oil for treatment of psoriasis.","volume":"100","author":"Tveit","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ahj.2014.08.007","article-title":"Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study.","volume":"168","author":"Andersson","year":"2014","journal-title":"Am Heart J."},{"key":"B47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126561","article-title":"Aberrations in lipid expression and metabolism in psoriasis.","volume":"22","author":"Nowowiejska","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1016\/s0002-9343(98)00041-2","article-title":"Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization.","volume":"104","author":"Libby","year":"1998","journal-title":"Am J Med."},{"key":"B49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","article-title":"New cardiovascular prevention guidelines: how to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?","volume":"319","author":"Atar","year":"2021","journal-title":"Atherosclerosis."},{"key":"B50","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/ciia.2006.1.4.433","article-title":"Management of hyperlipidemia with statins in the older patient.","volume":"1","author":"Aronow","year":"2006","journal-title":"Clin Interv Aging."},{"key":"B51","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0378-6323.188655","article-title":"The effect of statins on severity of psoriasis: a systematic review.","volume":"83","author":"Ramessur","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000572","article-title":"Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis.","volume":"94","author":"Xing","year":"2015","journal-title":"Medicine."},{"key":"B53","first-page":"69","article-title":"The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis.","volume":"33","author":"Lv","year":"2015","journal-title":"Clin Exp Rheumatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1007\/s00296-012-2613-z","article-title":"The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: a pilot study.","volume":"33","author":"Shirinsky","year":"2013","journal-title":"Rheumatol Int."},{"key":"B55","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jacc.2007.04.076","article-title":"Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis.","volume":"50","author":"Maki-Petaja","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"B56","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade.","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ahj.2015.11.015","article-title":"Rationale and design of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk trial.","volume":"173","author":"Sabatine","year":"2016","journal-title":"Am Heart J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","article-title":"Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.","volume":"178","author":"Ridker","year":"2016","journal-title":"Am Heart J."},{"key":"B59","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J."},{"key":"B60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","article-title":"Statin drug interactions and related adverse reactions: an update.","volume":"17","author":"Bellosta","year":"2018","journal-title":"Expert Opin Drug Saf."},{"key":"B61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy.","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur J Pharmacol."},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020723","article-title":"Oxidative stress and lipid mediators modulate immune cell functions in autoimmune diseases.","volume":"22","author":"W\u00f3jcik","year":"2021","journal-title":"Int J Mol Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/2277-9175.124639","article-title":"Efficacy of adding topical simvastatin to topical calcipotriol on improvement of cutaneous plaque psoriasis.","volume":"3","author":"Iraji","year":"2014","journal-title":"Adv Biomed Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jaad.2007.05.040","article-title":"Efficacy of simvastatin in plaque psoriasis: A pilot study. J Am Acad Dermatol","volume":"57","author":"Shirinsky","year":"2007"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.900916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T10:11:48Z","timestamp":1660212708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.900916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":64,"alternative-id":["10.3389\/fmed.2022.900916"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.900916","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fmed.2022.900916.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fmed.2022.900916.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fmed.2022.900916.s003","asserted-by":"subject"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"article-number":"900916"}}